Non-Small Cell Lung Cancer Coverage from Every Angle

ORIENT-12 Trial: Sintilimab Plus Standard Chemotherapy for Metastatic Lung Cancer

By: Justine Landin, PhD
Posted: Wednesday, June 23, 2021

Addition of the anti–PD-1 antibody sintilimab to standard platinum and gemcitabine chemotherapy may improve clinical outcomes for patients with squamous non–small cell lung cancer (NSCLC), according to results from the ORIENT-12 phase III trial. In particular, patients given sintilimab plus platinum/gemcitabine had increased progression-free survival compared with those given placebo plus platinum/gemcitabine. The results of this multicenter, randomized, double-blind study were published in the Journal of Thoracic Oncology.

“The risk of disease progression or death was reduced by 37.9% at interim analysis and by 46.4% at updated analysis,” stated study author Caicun Zhou, MD, PhD, of Shanghai Pulmonary Hospital, in an International Association for the Study of Lung Cancer press release. “The results from ORIENT-12 could provide a new option for combination therapy in this patient population.”

Patients with squamous NSCLC (stage 3 or 4) and at least one measurable lesion with no previous treatment for advanced or metastatic disease were enrolled (n = 543). Patients with EGFR-sensitive mutations or ALK rearrangements were excluded. Patients were randomly assigned to receive sintilimab (200 mg) or placebo, in addition to platinum and gemcitabine. Treatment was administered every 3 weeks for four to six cycles, and maintenance therapy was conducted for 2 years, or until disease progression. An independent radiographic review committee assessed the primary endpoints.

At the median follow-up of 12.9 months, those who received sintilimab exhibited higher rates of progression-free survival (22.3%) compared with those given placebo (3.1%; hazard ratio = 0.536; 95% confidence interval = 0.422–0.681; P < .00001). Although the median overall survival was not reached, the sintilimab-treated group appeared to exhibit a benefit trend compared with the placebo-treated group (P = .017).

Treatment-related adverse events of grade 3 or higher did not significantly differ between groups (87% with sintilimab, 83% with placebo). Regarding treatment-related deaths, 4.5% and 6.7% of deaths were attributed to the sintilimab and placebo treatments, respectively.  

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.